 |
21 Diseases |  |
0 Trials |
|
0 Trials |  |
21 News |  |
- | Algeron (cepeginterferon alfa-2b) / Biocad, hydrocortisone / Generic mfg.
Preclinical, Journal: Wound healing potential of Cystoseira/mesenchymal stem cells in immunosuppressed rats supported by overwhelming immuno-inflammatory crosstalk. (Pubmed Central) - Apr 8, 2024
From constructed PPI network for wound healing and further analysis through molecular docking and molecular dynamics (MD) simulation experiments suggested that cystalgerone metabolite may be responsible for the wound healing-promoting effect of Cystoseira extract...Sixteen d after immunity suppression (by 40 mg/kg hydrocortisone daily), an incision was made in the dorsal skin of the rat...Our research indicates that the primary compounds of Cystoseira holds potential wound healing therapeutic activity. Although more safety testing and clinical studies are required, the combination has great potential for regenerative medicine and could be a revolutionary advance in the healing of the wounds of immunosuppressed patients.
- || Algeron (cepeginterferon alfa-2b) / Biocad
The many therapies currently in development based on #biologicalgerontology principles provide promise for the development of a new generation of therapeutics to #prevent and #treat #alzheimerdisease @hfillit @GreenJournal @INSPIREPlatfor1 https://t.co/BRhVXirLur (Twitter) - Aug 15, 2021
- || Algeron (cepeginterferon alfa-2b) / Biocad
#biomedicalgerontology.comn https://t.co/2eC5W1wGXS (Twitter) - Mar 1, 2021
- || Algeron (cepeginterferon alfa-2b) / Biocad
#somaticepitype not 1 size fits all pharmaceuticals - #BiomedicalGerontology.com (Twitter) - Mar 1, 2021
- |||||| Algeron (cepeginterferon alfa-2b) / Biocad
Clinical: #FollowFriday these Tweeps: @PaganoniMDPhD @ciaswansea @PatientVoices @DeVorePremier @UoDMHN @CarebuildAtHome @AnglerMD @BarnetCarers @HenryBodkin @SchaefferCenter @samstuart87 @VisualGeron @WriterDMac @MorieSmile @dsouzamichaelc @Alzheimeric @BeccaCFarley @VindellW @cindy_wallis (Twitter) - May 29, 2020
- || Algeron (cepeginterferon alfa-2b) / Biocad
Loved all of CS Lewis and my daughter just read Flowers for Algeron so I got to revisit that as well (Twitter) - Feb 20, 2020
- | Algeron (cepeginterferon alfa-2b) / Biocad
Journal: Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. (Pubmed Central) - Apr 5, 2019
The estimated therapeutic dose should be calculated according to body weight. To reduce the frequency of hematologic AE, titration of the drug dose is required.
- ||||| Algeron (cepeginterferon alfa-2b) / Biocad
Trial completion, Combination therapy: An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients (clinicaltrials.gov) - Aug 9, 2018
P3, N=140, Completed, Sponsor: Biocad
To reduce the frequency of hematologic AE, titration of the drug dose is required. Active, not recruiting --> Completed
- ||||| Algeron (cepeginterferon alfa-2b) / Biocad
Trial completion, Enrollment change: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C (clinicaltrials.gov) - Jul 16, 2018
P3, N=170, Completed, Sponsor: Biocad
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=500 --> 170
- ||||| Algeron (cepeginterferon alfa-2b) / Biocad
Enrollment closed: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C (clinicaltrials.gov) - Nov 15, 2015
P3, N=500, Active, not recruiting, Sponsor: Biocad
Active, not recruiting --> Completed | N=500 --> 170 Recruiting --> Active, not recruiting
- |||||||||| Algeron (cepeginterferon alfa-2b) / Biocad
New P3 trial, Combination therapy, IO biomarker: An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients (clinicaltrials.gov) - Apr 1, 2014
P3, N=140, Active, not recruiting, Sponsor: Biocad
- ||||| Algeron (cepeginterferon alfa-2b) / Biocad
Trial initiation date: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C (clinicaltrials.gov) - Jan 9, 2014
P3, N=500, Recruiting, Sponsor: Biocad
Recruiting --> Active, not recruiting Initiation date: Jul 2013 --> Nov 2013
- |||||| Algeron (cepeginterferon alfa-2b) / Biocad
Enrollment open: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C (clinicaltrials.gov) - Jan 9, 2014
P3, N=500, Recruiting, Sponsor: Biocad
Initiation date: Jul 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- ||||||| Algeron (cepeginterferon alfa-2b) / Biocad
Trial completion: Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C (clinicaltrials.gov) - Jan 8, 2014
P2/3, N=150, Completed, Sponsor: Biocad
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Algeron (cepeginterferon alfa-2b) / Biocad
New P3 trial: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C (clinicaltrials.gov) - Jun 26, 2013
P3, N=500, Recruiting, Sponsor: Biocad
- |||||||||| Algeron (cepeginterferon alfa-2b) / Biocad
New P2/3 trial: Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C (clinicaltrials.gov) - Dec 2, 2012
P2/3, N=150, Completed, Sponsor: Biocad